Procyrion is proud to be recognized as a Fierce15 Medtech company this year! Check out the interview with our CEO Eric Fain to learn more about our innovative Aortix™ technology and the potential it has to change the way patients with acute decompensated heart failure and cardiorenal syndrome are treated. Read more…
Procyrion Recognized in Fierce Medtech’s Fierce15 of 2023 Read More »
Innovative collaboration will improve patient outcomes and cost savings through reduced trial-and-error management of biologic therapies Mindera Health, developer of Mind.Px™, the first realization of precision medicine in psoriasis, has formed a partnership with LivinitiTM, an innovative Pharmacy Benefit Manager, to improve the management of moderate-to-severe psoriasis patients. This pilot program will utilize Mind.Px to
Podimetrics – Revolutionize diabetic foot care for your patients Skip to main content Skip to footer Download our new eBook today! Breaking Barriers: Combatting Diabetic Amputations in Communities of ColorPeople of Color bear the heaviest
Revolutionize diabetic foot care for your patients Read More »
HOUSTON, TX – February 5, 2024 – Procyrion™, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today the completion of a $57.7 million Series E funding round, including the conversion of $10.0 million of interim financing. These funds will be used to support the ongoing DRAIN-HF
Procyrion Closes $57.7 Million in Series E Financing Read More »
February 2, 2024 – Woburn, MA Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription product offerings, today announced that the company will be participating in the 2024 International Master Course on Aging Science (IMCAS) World Congress, taking place February 1 – 3, 2024, in Paris. Chief Executive Officer and President, Jon
Eirion Therapeutics to Present at the 2024 IMCAS World Congress Read More »
HOUSTON, TX – NOVEMBER 30, 2023 – Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced the enrollment of the first patients in the company’s IDE pivotal trial. The DRAIN-HF (Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure) study will evaluate the Aortix™ percutaneous
San Diego, CA – November 27th, 2023 – Mindera Health™, a leading provider of precision medicine solutions for psoriasis, today announced that it will be relocating its commercial activities to a new office building at 1221 Liberty Way, Vista, CA 92081 on December 1st, 2023. The new facility is over 19,000 square feet and features
Mindera Health ™ Announces Commercial Relocation Read More »
Company secures funding to fuel expansion of its Thoraguard® System; adds veteran medtech leader Timothy Still to Board of Directors Centese, Inc., a leader in digital surgery technology, announces the successful closing of its $15M Series B funding round. The round, led by Medical Technology Venture Partners with participation from new and existing investors, will
Centese, Inc. Secures Series B Funding and Strengthens Board With New Director – Read More »
OAKLAND, Calif. and NEW YORK, NY, Nov.15, 2023 OrbiMed, a leading healthcare investment firm and Koya Medical, a healthcare company with a mission to transform venous and lymphatic treatments through novel, people-centric solutions, today announced the closing of a financing for up to $30 million. The capital will support the company’s strategic expansion and continued
Koya Medical Raises New Capital with OrbiMed to Support Growth Read More »
San Diego, CA, Nov. 06, 2023 (GLOBE NEWSWIRE) — Mindera Health today announces the signing a commercial agreement with Occum Health, LLC, a healthcare solutions company that is focused on delivering savings and improved benefits to self-insured employers. Through this agreement, Mindera’s proprietary psoriasis biologic prediction test, Mind.Px, is available to Occum Health’s more than